【TAIPEI, August 18, 2025】— Topmunnity Therapeutics Taiwan Limited is proud to announce today that it has become a member of the NVIDIA Inception program. Topmunnity Therapeutics will leverage NVIDIA's powerful AI platform and the resources provided by the NVIDIA Inception program to supercharge the company's core technologies and accelerate its mission of integrating high-speed engineering computing with biotechnology to drive new drug development.

​

The NVIDIA Inception program is a global initiative designed to assist startups in adopting new technologies and provide professional guidance. It offers in-depth guidance using NVIDIA's technical resources to help promising local startup teams grow, validate product/service concepts, and provide opportunities for business exchange and media exposure. The program is dedicated to helping startups seize opportunities, achieve breakthrough developments in the fields of artificial intelligence and data science, and successfully expand onto the international stage.

​

Topmunnity Therapeutics CEO, Chao-Yuan Huang, stated: " We are grateful for NVIDIA's recognition of our innovative technological strength. Joining the NVIDIA Inception program is a key step in realizing our mission to use Tech Bio as the main axis to accelerate new drug development. Through NVIDIA's world-class computing power and professional technical support, we will be able to significantly enhance the efficiency of AI model training and molecular dynamics simulations, accelerating our ADC drug development from concept to clinic and bringing more hopeful treatment options to cancer patients."

​

Topmunnity Therapeutics' core competitiveness lies in its unique "AI + Product" dual-engine strategy, which integrates the proprietary DynAbind.AI platform with advanced ADC drug development. The company's lead ADC candidate, TT-01 ADC, has demonstrated outstanding efficacy and safety in preclinical models. The superior characteristics of TT-01 ADC serve as a valuable foundation for training and design of our AI platform, leveraging its enormous potential to innovate AI platforms and create new opportunities in the pharmaceutical market.

​

As a member of the NVIDIA Inception program, Topmunnity Therapeutics will be able to more deeply integrate NVIDIA's computing resources and software, which will not only accelerate the R&D progress of our existing products but also lay a solid foundation for the future discovery and optimization of more AI-generated antibody drugs.

 

​

About Topmunnity Therapeutics Taiwan Limited

Topmunnity Therapeutics Taiwan Limited is an innovative biopharmaceutical company dedicated to the deep integration of artificial intelligence and biomedicine. Through its proprietary AI platform and advanced drug development pipeline, it aims to solve the pain points of traditional drug development and provide more effective and precise next-generation solutions for cancer treatment.

​​​

​

Media Contact:

Andrea Yang

Finance Manager

info@topmunnity.com

+886-2-2301-2180

www.topmunnity.com